The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

Identifying copyright holders and response times are major challenges in COA licensing, causing delays in clinical trials. Clear documentation of copyright ownership and standardized response times ...

Examine the strategies community research sites can use to secure trial opportunities, from adopting AI-enabled workflows to ...

In today’s ACT Brief, we examine how community research sites can stay competitive under rising efficiency pressures, why ...

Real-world adverse events are rarely monocausal. They emerge from the interaction of drug exposure, comorbid conditions, physiological states, concomitant medications, and patient-specific ...

Pharmacovigilance has advanced in detecting population-level safety signals, but a critical gap remains in translating those insights into transparent, defensible patient-level decisions.

Unpack how rising competition for the same high-profile sites is slowing startup and enrollment—and what sponsors must change ...

In today’s ACT Brief, we hear how sponsors may redefine efficiency to protect patient access in 2026, review Verana Health’s ...

The merger enhances Verana Health's data capabilities across oncology, ophthalmology, urology, and neurology, supporting clinical research and regulatory decision-making. Integration of COTA's ...

Explore how sponsors can recalibrate efficiency efforts to avoid overconcentrating trials at familiar sites and instead ...

In today’s ACT Brief, we examine the growing challenges of sourcing comparator drugs across the EU, highlight a new AI-driven ...